Profile data is unavailable for this security.
About the company
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
- Revenue in GBP (TTM)0.00
- Net income in GBP-8.41m
- Incorporated2004
- Employees36.00
- LocationSynairgen PLCSouthampton General Hosp, Tremona RoadSOUTHAMPTON SO16 6YDUnited KingdomGBR
- Phone+44 238 051 2800
- Fax+44 238 051 2800
- Websitehttps://www.synairgen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
| ValiRx Plc | 9.60k | -2.04m | 2.98m | 8.00 | -- | 0.7153 | -- | 310.19 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| TheraCryf PLC | 396.00k | -3.14m | 2.99m | 9.00 | -- | 0.822 | -- | 7.55 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| Fusion Antibodies PLC | 1.58m | -2.84m | 3.19m | 50.00 | -- | 1.37 | -- | 2.02 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| IXICO PLC | 6.00m | -1.87m | 4.59m | 89.00 | -- | 0.4576 | -- | 0.7656 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| ImmuPharma PLC | 0.00 | -2.92m | 5.82m | 5.00 | -- | 5.51 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 6.34m | 67.00 | -- | 3.86 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.67m | 7.01m | 12.00 | -- | 3.04 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0279 | 0.00 | -- | -- | 0.00 | -82.98 | -- | -98.20 | -- | -- | -- | -- | -- | -- | -- | 0.0809 | -- | -- | -- | -1.92 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.63m | 7.69m | 5.00 | -- | 8.86 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| Synairgen plc | 0.00 | -8.41m | 7.76m | 36.00 | -- | 0.6133 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| LungLife AI Inc | 34.82k | -4.10m | 8.58m | 15.00 | -- | 0.5585 | -- | 246.43 | -0.1608 | -0.1608 | 0.0014 | 0.2351 | 0.0038 | -- | 0.2831 | 2,321.65 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 17.36m | 17.00 | -- | 5.40 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Oxford Biodynamics PLC | 617.00k | -11.11m | 21.36m | 45.00 | -- | 8.54 | -- | 34.62 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
Data as of Aug 23 2024. Currency figures normalised to Synairgen PLC's reporting currency: UK Pound GBX
38.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| TFG Asset Management UK LLPas of 26 Apr 2023 | 56.70m | 28.15% |
| Link Fund Solutions Ltd.as of 30 Jun 2019 | 21.34m | 10.60% |
Data from 30 Apr 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
